All trials View full record on ClinicalTrials.gov
NCT05834296PHASE1ACTIVE NOT RECRUITING
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
✨ Plain-English version on the way · ~2 days
We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.Read full record on ClinicalTrials.gov
Eligibility check — Phoenix members
Phoenix members see for THIS trial:
- APOE genotype match
- Cognitive status fits inclusion
- Specific exclusions flagged
- Distance to nearest site
Sites
1 location
Start
2023-07-05
Interventions tested
- BIOLOGICALALZN002 (autologous DCs pulsed with E22W mutant peptide).
- DRUGPlacebo